Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + Budigalimab
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Human Immuno-deficiency Virus (HIV) Disease
Conditions
Human Immuno-deficiency Virus (HIV) Disease
Trial Timeline
Oct 12, 2023 → Sep 22, 2025
NCT ID
NCT06032546About Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + Budigalimab
Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + Budigalimab is a phase 2 stage product being developed by AbbVie for Human Immuno-deficiency Virus (HIV) Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT06032546. Target conditions include Human Immuno-deficiency Virus (HIV) Disease.
What happened to similar drugs?
14 of 20 similar drugs in Human Immuno-deficiency Virus (HIV) Disease were approved
Approved (14) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06032546 | Phase 2 | Terminated |
Competing Products
20 competing products in Human Immuno-deficiency Virus (HIV) Disease